

In the Claims

Claims 1-28 (canceled)

29. (Currently amended): A method to identify a biological sample that exhibits dysregulated cellular growth comprising:

determining the level of 20P2H8 gene (SEQ ID NO: 1) expression in a test biological sample;

providing the level of 20P2H8 gene (SEQ ID NO: 1) expression in a normal sample of the same tissue type as the biological sample;

comparing the level of 20P2H8 gene (SEQ ID NO: 1) expression in the biological sample to the level of 20P2H8 gene (SEQ ID NO: 1) expression in a ~~corresponding~~ normal sample, wherein an ~~alteration~~ increase in the level of 20P2H8 gene (SEQ ID NO: 1) expression in the ~~biological test~~ sample as compared to the normal sample identifies the ~~biological test~~ sample as exhibiting dysregulated cellular growth.

30. (Currently amended): A method of identifying the presence of a neoplasm in a biological sample comprising:

(a) determining a level of 20P2H8 gene (SEQ ID NO: 1) expression in a test biological sample; and

(b) comparing the level of 20P2H8 gene (SEQ ID NO: 1) expression in the test biological sample to a level of 20P2H8 gene expression found in a ~~comparable~~ normal biological sample of the same tissue type as the test biological sample,

wherein a ~~difference~~ an increase in the level of 20P2H8 gene (SEQ ID NO: 1) expression in the test biological sample relative to the normal biological sample identifies the presence of the neoplasm.

Claim 31 (canceled)

32. (Currently amended): A method of diagnosing the presence of cancer in an individual comprising:

- (a) determining the level of 20P2H8 gene (SEQ ID NO: 1) expression in a test sample obtained from the individual; and
- (b) comparing the level so determined to the level of 20P2H8 gene (SEQ ID NO: 1) expression in a ~~comparable~~ known normal tissue sample of the same tissue type as the test sample, wherein elevated 20P2H8 gene (SEQ ID NO: 1) expression in the test sample relative to the normal tissue sample is diagnostic of ~~diagnoses~~ the presence of cancer.

Claims 33-43 (canceled)

44. (previously added): The method of claim 29, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA or by determining the level of 20P2H8 protein in said samples.

45. (previously added): The method of claim 44, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA.

Claims 46-49 (previously added; withdrawn)

50. (previously added): The method of claim 30, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA or by determining the level of 20P2H8 protein in said samples.

51. (previously added): The method of claim 50, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA.

Claims 52-55 (previously added; withdrawn)

56. (previously added): The method of claim 32, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA or by determining the level of 20P2H8 protein in said samples.

57. (previously added): The method of claim 56, wherein the level of 20P2H8 gene expression is determined by determining the level of 20P2H8 mRNA.

02
argued
Claims 58-61 (previously added; withdrawn)
